Talzenna is currently approved in combination with Xtandi (enzalutamide) for individuals with castration-resistant prostate ...

In a somber end to an FDA advisory committee’s two-day scouring of multiple drugmakers’ oncology data, Pfizer’s pitch to ...

An eight-member panel voted unanimously against wider use of Pfizer’s Talzenna in advanced prostate cancer. Elsewhere, U.K.

Emilio Parra Doiztua / Bloomberg / Getty Images Pfizer said late Monday that it has agreed to a deal to help develop and market a Chinese cancer drug across the globe. Chinese firm 3SBio is ...

WASHINGTON — The release of COVID-19 vaccine results after the 2020 election may have not been a “coincidence” — and could have been part of an effort by senior Pfizer executives to ...

US drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc, paying $1.25 billion upfront and up to another $4.8 billion if developmental milestones are met.

Pfizer (NYSE:PFE) has signed an exclusive global licensing deal with China’s 3SBio for the development of its cancer drug candidate, SSGJ-707. SSGJ-707, a bispecific antibody targeting PD-1 and ...

While Pfizer Ltd had reported Rs179 crore In the corresponding quarter of the previous fiscal, or March quarter of FY24, the net profit in the March 2025 quarter saw a sharp jump to ₹331 crore.

One patient in the 25 mg group died from a fatal case of COVID-19. Tourmaline heads to Nasdaq, inking Talaris reverse merger to fund midphase trials of Pfizer castoff Interleukin-6 is a ...

Shares of Pfizer jumped by as much as 11 percent to Rs 4,995 apiece on May 20 after the company posted a strong performance for the March quarter (Q4FY25). In the past month, this pharma stock ...

Pfizer has joined the ranks of companies developing cancer drugs that target both PD-1 and VEGF – one of the hottest drug classes in oncology, via a $6 billion licensing deal with China's 3SBio.

Pfizer-backed CellCentric has secured $120 million in series C funds as the British biotech prepares to take its multiple myeloma drug into pivotal trials. The candidate in question, an oral p300 ...